InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Collaborates With Makana Therapeutics on Xenotransplantation Research
Tonix Pharmaceuticals (NASDAQ: TNXP) announced a research collaboration with Makana Therapeutics to evaluate TNX-1500, its anti-CD40L monoclonal antibody candidate, in preclinical studies alongside Makana’s human-compatible organs and cells. The studies aim to support a future investigational new drug application to the FDA for compassionate use in xenotransplantation. Makana’s genetically engineered pigs, designed without swine leukocyte antigen, have demonstrated improved human compatibility, positioning both companies to…